Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

The VISIONARY Study Group

doi:10.1007/s12325-022-02210-5

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

The VISIONARY Study Group

Neiromedicīnas un neirozinātņu nodaļa

IRCCS Fondazione G.B. Bietti per lo studio e la ricerca in oftalmologia - Roma
Portsmouth Hospitals University NHS Trust
Instituto Oftalmologico Gomez-Ulla
LLC Vzglyad
Santen SA
Tutkimusz Ltd
Prima Medica Health Centers

Zinātniskās darbības rezultāts: Devums žurnālam › Komentārs/diskusija/piezīme

1 Atsauce (Scopus)

Kopsavilkums

The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

Oriģinālvaloda	Angļu
Lapas (no-līdz)	3522-3523
Lapu skaits	2
Žurnāls	Advances in Therapy
Sējums	39
Izdevuma numurs	8
DOIs	https://doi.org/10.1007/s12325-022-02210-5
Publikācijas statuss	Publicēts - 1 aug. 2022

Piekļuve Dokumentiem

10.1007/s12325-022-02210-5

Citi faili un saites

Saite uz publikāciju Scopus

Nospiedums

Uzziniet vairāk par pētniecības tēmām “Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)”. Kopā tie veido unikālu nospiedumu.

Citēt šo

The VISIONARY Study Group (2022). Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). Advances in Therapy, 39(8), 3522-3523. https://doi.org/10.1007/s12325-022-02210-5

The VISIONARY Study Group. / Correction to : Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). (gadā): Advances in Therapy. 2022 ; Sēj. 39, Nr. 8. lpp. 3522-3523.

@article{b813f657d7f249d2913f69e4d9c7c98c,

title = "Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)",

abstract = "The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9\%; p\textbackslash{}0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.",

author = "\{The VISIONARY Study Group\} and Francesco Oddone and James Kirwan and Fernando Lopez-Lopez and Marina Zimina and Claudia Fassari and G{\'a}bor Holl{\'o} and Christoph Faschinger and Enping Chen and Gabor Nemeth and Gyorgy Bator and Alexis Tsorbatzoglou and Tamas Acs and Maria Ferencz and Zolt{\'a}n Sohajda and Jeno Toth and Veronika Volner and G{\'a}bor Vogt and Zsolt Biro and Andrea Facsk{\'o} and J{\'a}nos Nemes and Andras Berta and Ilona Elek and Eugene Ng and Gemma Rossi and Luca Rossetti and Michele Vetrugno and Michele Iester and Giorgio Marchini and Vincenzo Scorcia and Giovanni Staurenghi and Carlo Cagini and Tommaso Salgarello and Paolo Bettin and Michele Figus and Scuderi, \{Gian Luca\} and \{De Cilla\}, Stefano and Iveta Grundmane and Nora Linavska and Lasma Volksone and Guna Laganovska and Kristine Baumane and Hans Lemij and Gundersen, \{Kjell Gunnar\} and Valery Erichev and Elmira Adbulaeva and Elena Karlova and Ekaterina Zakharova and Irina Panova and Boris Malyugin and I{\~n}aki Rodr{\'i}guez-Agirretxe",

note = "Publisher Copyright: {\textcopyright} Springer Healthcare Ltd., part of Springer Nature 2022.",

year = "2022",

month = aug,

day = "1",

doi = "10.1007/s12325-022-02210-5",

language = "English",

volume = "39",

pages = "3522--3523",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Adis",

number = "8",

}

The VISIONARY Study Group 2022, 'Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)', Advances in Therapy, sēj. 39, Nr. 8, lpp. 3522-3523. https://doi.org/10.1007/s12325-022-02210-5

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). / The VISIONARY Study Group.
(gadā): Advances in Therapy, Sēj. 39, Nr. 8, 01.08.2022, lpp. 3522-3523.

Zinātniskās darbības rezultāts: Devums žurnālam › Komentārs/diskusija/piezīme

TY - JOUR

T1 - Correction to

T2 - Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)

AU - The VISIONARY Study Group

AU - Oddone, Francesco

AU - Kirwan, James

AU - Lopez-Lopez, Fernando

AU - Zimina, Marina

AU - Fassari, Claudia

AU - Holló, Gábor

AU - Faschinger, Christoph

AU - Chen, Enping

AU - Nemeth, Gabor

AU - Bator, Gyorgy

AU - Tsorbatzoglou, Alexis

AU - Acs, Tamas

AU - Ferencz, Maria

AU - Sohajda, Zoltán

AU - Toth, Jeno

AU - Volner, Veronika

AU - Vogt, Gábor

AU - Biro, Zsolt

AU - Facskó, Andrea

AU - Nemes, János

AU - Berta, Andras

AU - Elek, Ilona

AU - Ng, Eugene

AU - Rossi, Gemma

AU - Rossetti, Luca

AU - Vetrugno, Michele

AU - Iester, Michele

AU - Marchini, Giorgio

AU - Scorcia, Vincenzo

AU - Staurenghi, Giovanni

AU - Cagini, Carlo

AU - Salgarello, Tommaso

AU - Bettin, Paolo

AU - Figus, Michele

AU - Scuderi, Gian Luca

AU - De Cilla, Stefano

AU - Grundmane, Iveta

AU - Linavska, Nora

AU - Volksone, Lasma

AU - Laganovska, Guna

AU - Baumane, Kristine

AU - Lemij, Hans

AU - Gundersen, Kjell Gunnar

AU - Erichev, Valery

AU - Adbulaeva, Elmira

AU - Karlova, Elena

AU - Zakharova, Ekaterina

AU - Panova, Irina

AU - Malyugin, Boris

AU - Rodríguez-Agirretxe, Iñaki

PY - 2022/8/1

Y1 - 2022/8/1

N2 - The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

AB - The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.

UR - https://www.scopus.com/pages/publications/85133655439

U2 - 10.1007/s12325-022-02210-5

DO - 10.1007/s12325-022-02210-5

M3 - Comment/debate/note

C2 - 35731341

AN - SCOPUS:85133655439

SN - 0741-238X

VL - 39

SP - 3522

EP - 3523

JO - Advances in Therapy

JF - Advances in Therapy

IS - 8

ER -

The VISIONARY Study Group. Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6). Advances in Therapy. 2022 aug. 1;39(8):3522-3523. doi: 10.1007/s12325-022-02210-5